Biotech Values

[DewDiligence]

FDA approves Tivicay (f/k/a dolutegravir), an integrase inhibitor for HIV:

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm364744.htm

The label includes both first- and second-line use. Tivicay’s competition is GILD’s Stribild/Elvitegravir and MRK’s Isentress.

Tivicay belongs to the ViiV Healthcare JV, which is owned 76.5% by GSK, 13.5% by PFE, and 10% by Shionogi. GSK is the manufacturer.